It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Retinal thickness may serve as a biomarker in Parkinson’s disease (PD). In this prospective longitudinal study, we aimed to determine if PD patients present accelerated thinning rate in the parafoveal ganglion cell-inner plexiform layer (pfGCIPL) and peripapillary retinal nerve fiber layer (pRNFL) compared to controls. Additionally, we evaluated the relationship between retinal neurodegeneration and clinical progression in PD. A cohort of 156 PD patients and 72 controls underwent retinal optical coherence tomography, visual, and cognitive assessments between February 2015 and December 2021 in two Spanish tertiary hospitals. The pfGCIPL thinning rate was twice as high in PD (β [SE] = −0.58 [0.06]) than in controls (β [SE] = −0.29 [0.06], p < 0.001). In PD, the progression pattern of pfGCIPL atrophy depended on baseline thickness, with slower thinning rates observed in PD patients with pfGCIPL below 89.8 µm. This result was validated with an external dataset from Moorfields Eye Hospital NHS Foundation Trust (AlzEye study). Slow pfGCIPL progressors, characterized by older at baseline, longer disease duration, and worse cognitive and disease stage scores, showed a threefold increase in the rate of cognitive decline (β [SE] = −0.45 [0.19] points/year, p = 0.021) compared to faster progressors. Furthermore, temporal sector pRNFL thinning was accelerated in PD (βtime x group [SE] = −0.67 [0.26] μm/year, p = 0.009), demonstrating a close association with cognitive score changes (β [SE] = 0.11 [0.05], p = 0.052). This study suggests that a slower pattern of pfGCIPL tissue loss in PD is linked to more rapid cognitive decline, whereas changes in temporal pRNFL could track cognitive deterioration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Romero-Bascones, David 2 ; Teijeira-Portas, Sara 3 ; Urcola, J. Aritz 4 ; Ruiz-Martínez, Javier 5 ; Del Pino, Rocío 6
; Acera, Marian 6 ; Petzold, Axel 7
; Wagner, Siegfried Karl 8 ; Keane, Pearse Andrew 8 ; Ayala, Unai 9
; Barrenechea, Maitane 9
; Tijero, Beatriz 10 ; Gómez Esteban, Juan Carlos 11
; Gabilondo, Iñigo 12
1 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000 0001 2167 1098)
2 Biomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Mondragón, Spain (GRID:grid.436417.3) (ISNI:0000 0001 0662 2298); NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837)
3 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.439257.e)
4 Araba University Hospital, Department of Ophthalmology, Vitoria-Gasteiz, Spain (GRID:grid.439257.e)
5 Donostia University Hospital, Department of Neurology, Donostia, Spain (GRID:grid.414651.3) (ISNI:0000 0000 9920 5292); Biogipuzkoa Health Research Institute, Donostia, Spain (GRID:grid.414651.3); CIBERNED, Institute of Health Carlos III, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
6 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.413448.e)
7 NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837); University College London, Queen Square Institute of Neurology, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201); The National Hospital for Neurology and Neurosurgery, London, UK (GRID:grid.436283.8) (ISNI:0000 0004 0612 2631); Amsterdam UMC, Departments of Neurology and Ophthalmology, Amsterdam, Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
8 NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837); University College London, Institute of Ophthalmology, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
9 Biomedical Engineering Department, Faculty of Engineering (MU-ENG), Mondragon Unibertsitatea, Mondragón, Spain (GRID:grid.436417.3) (ISNI:0000 0001 0662 2298)
10 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.436417.3); Cruces University Hospital, Neurology Department, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135)
11 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.411232.7); Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Leioa, Spain (GRID:grid.11480.3c) (ISNI:0000 0001 2167 1098); Cruces University Hospital, Neurology Department, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135)
12 Neurodegenerative Diseases Group, Biobizkaia Health Research Institute, Barakaldo, Spain (GRID:grid.411232.7); Cruces University Hospital, Neurology Department, Barakaldo, Spain (GRID:grid.411232.7) (ISNI:0000 0004 1767 5135); IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain (GRID:grid.424810.b) (ISNI:0000 0004 0467 2314)




